http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 09 Jul 2026 16:20:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++BIO-TECHNE+Corp++++++++++++++++++++++/26753458.html si-local-file:///var/storage/secattach/20260709/26753458.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++BIO-TECHNE+Corp++++++++++++++++++++++/26753458.html Thu, 09 Jul 2026 16:20:00 -0400 O.00096475 TECH http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++BIO-TECHNE+Corp++++++++++++++++++++++/26753458.html si-local-file:///var/storage/secattach/20260709/26753458.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++BIO-TECHNE+Corp++++++++++++++++++++++/26753458.html Thu, 09 Jul 2026 16:20:00 -0400 O.00096475 TECH http://www.streetinsider.com/Downgrades/RBC+Capital+Downgrades+Bio-Techne+Corp.+%28TECH%29+to+Sector+Perform/26748973.html <p>RBC Capital analyst Dan Leonard downgraded Bio-Techne Corp. (NASDAQ: TECH) from Outperform to Sector Perform with a price target of $73.00 (from $62.00).</p><p>The analyst comments: “We are downgrading Bio-Tech (TECH) to Sector Perform from Outperform and raising our price target to $73 from $62. The downgrade and price target change reflect our view that Merck KGaA will successfully close its proposed acquisition of Bio-Techne. We believe regulatory risk is minimal, don't see an interloper, and the price is fair by relevant comps.</p><p>Bio-Techne checks the boxes as a strategic fit. The protein reagents franchise is best-in-class and history shows demand for http://www.streetinsider.com/Downgrades/RBC+Capital+Downgrades+Bio-Techne+Corp.+%28TECH%29+to+Sector+Perform/26748973.html Thu, 09 Jul 2026 02:07:43 -0400 TECH http://www.streetinsider.com/Analyst+Comments/RBC+Capital+Downgrades+Bio-Techne+Corp.+%28TECH%29+to+Sector+Perform/26748973.html <p>RBC Capital analyst Dan Leonard downgraded Bio-Techne Corp. (NASDAQ: TECH) from Outperform to Sector Perform with a price target of $73.00 (from $62.00).</p><p>The analyst comments: “We are downgrading Bio-Tech (TECH) to Sector Perform from Outperform and raising our price target to $73 from $62. The downgrade and price target change reflect our view that Merck KGaA will successfully close its proposed acquisition of Bio-Techne. We believe regulatory risk is minimal, don't see an interloper, and the price is fair by relevant comps.</p><p>Bio-Techne checks the boxes as a strategic fit. The protein reagents franchise is best-in-class and history shows demand for http://www.streetinsider.com/Analyst+Comments/RBC+Capital+Downgrades+Bio-Techne+Corp.+%28TECH%29+to+Sector+Perform/26748973.html Thu, 09 Jul 2026 02:07:43 -0400 TECH http://www.streetinsider.com/Corporate+News/Bio-Techne+expands+AI-engineered+protein+portfolio+for+cell+therapy/26743926.html <p>Bio-Techne Corporation (NASDAQ: TECH) announced the launch of five new proteins added to its R&D Systems AI-Engineered Designer Protein portfolio, according to a company press release dated July 8, 2026.</p><p>The new additions include FGF-4 Heat Stable, FGF-7 Heat Stable, FGF-8b Heat Stable, IL-3 Heat Stable, and IL-15 Hyperactive. These proteins span the fibroblast growth factor and interleukin cytokine families and are designed for use in cell therapy development, stem cell culture, organoid expansion, and regenerative medicine workflows.</p><p>The proteins are engineered using AI-guided design with the goal of improving heat stability, activity, and solubility in cell culture applications. Bio-Techne states the http://www.streetinsider.com/Corporate+News/Bio-Techne+expands+AI-engineered+protein+portfolio+for+cell+therapy/26743926.html Wed, 08 Jul 2026 06:30:59 -0400 TECH http://www.streetinsider.com/Press+Releases/Bio-Techne+Launches+Expanded+R%26amp%3BD+Systems+AI-Engineered+Designer+Protein+Portfolio/26743909.html <div class="xn-content"> <p class="prntac"><i>Advancing Scalable Reproducible Cell Therapy and Advanced Cell Culture Workflows</i></p><ul type="disc"><li>New heat-stable and hyperactive proteins across the fibroblast growth factor and interleukin cytokine families expand the R&amp;D Systems™ AI-Engineered Designer Protein portfolio<br /><br /></li><li>AI-guided protein design supports improved consistency, performance and scalability in complex cell culture workflows<br /><br /></li><li>Engineered signaling proteins help address key challenges in scaling cell therapy from discovery through manufacturing</li></ul><p><span class="legendSpanClass"><location value="LU/us.mn.minnea" idsrc="xmltag.org" >MINNEAPOLIS</location></span>, <span class="legendSpanClass"><chron>July 8, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TECH" idsrc="xmltag.org" >Bio-Techne Corporation</span> (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced the launch of new additions http://www.streetinsider.com/Press+Releases/Bio-Techne+Launches+Expanded+R%26amp%3BD+Systems+AI-Engineered+Designer+Protein+Portfolio/26743909.html Wed, 08 Jul 2026 06:30:00 -0400 A.28110669 A.50204289 O.00052604 O.00096475 O.48401414 TECH http://www.streetinsider.com/Press+Releases/Bio-Techne+Launches+Expanded+R%26amp%3BD+Systems+AI-Engineered+Designer+Protein+Portfolio/26743909.html <div class="xn-content"> <p class="prntac"><i>Advancing Scalable Reproducible Cell Therapy and Advanced Cell Culture Workflows</i></p><ul type="disc"><li>New heat-stable and hyperactive proteins across the fibroblast growth factor and interleukin cytokine families expand the R&amp;D Systems™ AI-Engineered Designer Protein portfolio<br /><br /></li><li>AI-guided protein design supports improved consistency, performance and scalability in complex cell culture workflows<br /><br /></li><li>Engineered signaling proteins help address key challenges in scaling cell therapy from discovery through manufacturing</li></ul><p><span class="legendSpanClass"><location value="LU/us.mn.minnea" idsrc="xmltag.org" >MINNEAPOLIS</location></span>, <span class="legendSpanClass"><chron>July 8, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TECH" idsrc="xmltag.org" >Bio-Techne Corporation</span> (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced the launch of new additions http://www.streetinsider.com/Press+Releases/Bio-Techne+Launches+Expanded+R%26amp%3BD+Systems+AI-Engineered+Designer+Protein+Portfolio/26743909.html Wed, 08 Jul 2026 06:30:00 -0400 A.28110669 A.50204289 O.00052604 O.00096475 O.48401414 TECH http://www.streetinsider.com/Press+Releases/Bio-Techne+Launches+Expanded+R%26amp%3BD+Systems+AI-Engineered+Designer+Protein+Portfolio/26743909.html <div class="xn-content"> <p class="prntac"><i>Advancing Scalable Reproducible Cell Therapy and Advanced Cell Culture Workflows</i></p><ul type="disc"><li>New heat-stable and hyperactive proteins across the fibroblast growth factor and interleukin cytokine families expand the R&amp;D Systems™ AI-Engineered Designer Protein portfolio<br /><br /></li><li>AI-guided protein design supports improved consistency, performance and scalability in complex cell culture workflows<br /><br /></li><li>Engineered signaling proteins help address key challenges in scaling cell therapy from discovery through manufacturing</li></ul><p><span class="legendSpanClass"><location value="LU/us.mn.minnea" idsrc="xmltag.org" >MINNEAPOLIS</location></span>, <span class="legendSpanClass"><chron>July 8, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TECH" idsrc="xmltag.org" >Bio-Techne Corporation</span> (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced the launch of new additions http://www.streetinsider.com/Press+Releases/Bio-Techne+Launches+Expanded+R%26amp%3BD+Systems+AI-Engineered+Designer+Protein+Portfolio/26743909.html Wed, 08 Jul 2026 06:30:00 -0400 A.28110669 A.50204289 O.00052604 O.00096475 O.48401414 TECH http://www.streetinsider.com/Press+Releases/Bio-Techne+Launches+Expanded+R%26amp%3BD+Systems+AI-Engineered+Designer+Protein+Portfolio/26743909.html <div class="xn-content"> <p class="prntac"><i>Advancing Scalable Reproducible Cell Therapy and Advanced Cell Culture Workflows</i></p><ul type="disc"><li>New heat-stable and hyperactive proteins across the fibroblast growth factor and interleukin cytokine families expand the R&amp;D Systems™ AI-Engineered Designer Protein portfolio<br /><br /></li><li>AI-guided protein design supports improved consistency, performance and scalability in complex cell culture workflows<br /><br /></li><li>Engineered signaling proteins help address key challenges in scaling cell therapy from discovery through manufacturing</li></ul><p><span class="legendSpanClass"><location value="LU/us.mn.minnea" idsrc="xmltag.org" >MINNEAPOLIS</location></span>, <span class="legendSpanClass"><chron>July 8, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TECH" idsrc="xmltag.org" >Bio-Techne Corporation</span> (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced the launch of new additions http://www.streetinsider.com/Press+Releases/Bio-Techne+Launches+Expanded+R%26amp%3BD+Systems+AI-Engineered+Designer+Protein+Portfolio/26743909.html Wed, 08 Jul 2026 06:30:00 -0400 A.28110669 A.50204289 O.00052604 O.00096475 O.48401414 TECH http://www.streetinsider.com/Press+Releases/Bio-Techne+Launches+Expanded+R%26amp%3BD+Systems+AI-Engineered+Designer+Protein+Portfolio/26743909.html <div class="xn-content"> <p class="prntac"><i>Advancing Scalable Reproducible Cell Therapy and Advanced Cell Culture Workflows</i></p><ul type="disc"><li>New heat-stable and hyperactive proteins across the fibroblast growth factor and interleukin cytokine families expand the R&amp;D Systems™ AI-Engineered Designer Protein portfolio<br /><br /></li><li>AI-guided protein design supports improved consistency, performance and scalability in complex cell culture workflows<br /><br /></li><li>Engineered signaling proteins help address key challenges in scaling cell therapy from discovery through manufacturing</li></ul><p><span class="legendSpanClass"><location value="LU/us.mn.minnea" idsrc="xmltag.org" >MINNEAPOLIS</location></span>, <span class="legendSpanClass"><chron>July 8, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TECH" idsrc="xmltag.org" >Bio-Techne Corporation</span> (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced the launch of new additions http://www.streetinsider.com/Press+Releases/Bio-Techne+Launches+Expanded+R%26amp%3BD+Systems+AI-Engineered+Designer+Protein+Portfolio/26743909.html Wed, 08 Jul 2026 06:30:00 -0400 A.28110669 A.50204289 O.00052604 O.00096475 O.48401414 TECH http://www.streetinsider.com/Press+Releases/Bio-Techne+Launches+Expanded+R%26amp%3BD+Systems+AI-Engineered+Designer+Protein+Portfolio/26743909.html <div class="xn-content"> <p class="prntac"><i>Advancing Scalable Reproducible Cell Therapy and Advanced Cell Culture Workflows</i></p><ul type="disc"><li>New heat-stable and hyperactive proteins across the fibroblast growth factor and interleukin cytokine families expand the R&amp;D Systems™ AI-Engineered Designer Protein portfolio<br /><br /></li><li>AI-guided protein design supports improved consistency, performance and scalability in complex cell culture workflows<br /><br /></li><li>Engineered signaling proteins help address key challenges in scaling cell therapy from discovery through manufacturing</li></ul><p><span class="legendSpanClass"><location value="LU/us.mn.minnea" idsrc="xmltag.org" >MINNEAPOLIS</location></span>, <span class="legendSpanClass"><chron>July 8, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TECH" idsrc="xmltag.org" >Bio-Techne Corporation</span> (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced the launch of new additions http://www.streetinsider.com/Press+Releases/Bio-Techne+Launches+Expanded+R%26amp%3BD+Systems+AI-Engineered+Designer+Protein+Portfolio/26743909.html Wed, 08 Jul 2026 06:30:00 -0400 A.28110669 A.50204289 O.00052604 O.00096475 O.48401414 TECH http://www.streetinsider.com/PRNewswire/Bio-Techne+Launches+Expanded+R%26amp%3BD+Systems+AI-Engineered+Designer+Protein+Portfolio/26743909.html <div class="xn-content"> <p class="prntac"><i>Advancing Scalable Reproducible Cell Therapy and Advanced Cell Culture Workflows</i></p><ul type="disc"><li>New heat-stable and hyperactive proteins across the fibroblast growth factor and interleukin cytokine families expand the R&amp;D Systems™ AI-Engineered Designer Protein portfolio<br /><br /></li><li>AI-guided protein design supports improved consistency, performance and scalability in complex cell culture workflows<br /><br /></li><li>Engineered signaling proteins help address key challenges in scaling cell therapy from discovery through manufacturing</li></ul><p><span class="legendSpanClass"><location value="LU/us.mn.minnea" idsrc="xmltag.org" >MINNEAPOLIS</location></span>, <span class="legendSpanClass"><chron>July 8, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TECH" idsrc="xmltag.org" >Bio-Techne Corporation</span> (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced the launch of new additions http://www.streetinsider.com/PRNewswire/Bio-Techne+Launches+Expanded+R%26amp%3BD+Systems+AI-Engineered+Designer+Protein+Portfolio/26743909.html Wed, 08 Jul 2026 06:30:00 -0400 A.28110669 A.50204289 O.00052604 O.00096475 O.48401414 TECH http://www.streetinsider.com/PRNewswire/Bio-Techne+Launches+Expanded+R%26amp%3BD+Systems+AI-Engineered+Designer+Protein+Portfolio/26743909.html <div class="xn-content"> <p class="prntac"><i>Advancing Scalable Reproducible Cell Therapy and Advanced Cell Culture Workflows</i></p><ul type="disc"><li>New heat-stable and hyperactive proteins across the fibroblast growth factor and interleukin cytokine families expand the R&amp;D Systems™ AI-Engineered Designer Protein portfolio<br /><br /></li><li>AI-guided protein design supports improved consistency, performance and scalability in complex cell culture workflows<br /><br /></li><li>Engineered signaling proteins help address key challenges in scaling cell therapy from discovery through manufacturing</li></ul><p><span class="legendSpanClass"><location value="LU/us.mn.minnea" idsrc="xmltag.org" >MINNEAPOLIS</location></span>, <span class="legendSpanClass"><chron>July 8, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TECH" idsrc="xmltag.org" >Bio-Techne Corporation</span> (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced the launch of new additions http://www.streetinsider.com/PRNewswire/Bio-Techne+Launches+Expanded+R%26amp%3BD+Systems+AI-Engineered+Designer+Protein+Portfolio/26743909.html Wed, 08 Jul 2026 06:30:00 -0400 A.28110669 A.50204289 O.00052604 O.00096475 O.48401414 TECH http://www.streetinsider.com/PRNewswire/Bio-Techne+Launches+Expanded+R%26amp%3BD+Systems+AI-Engineered+Designer+Protein+Portfolio/26743909.html <div class="xn-content"> <p class="prntac"><i>Advancing Scalable Reproducible Cell Therapy and Advanced Cell Culture Workflows</i></p><ul type="disc"><li>New heat-stable and hyperactive proteins across the fibroblast growth factor and interleukin cytokine families expand the R&amp;D Systems™ AI-Engineered Designer Protein portfolio<br /><br /></li><li>AI-guided protein design supports improved consistency, performance and scalability in complex cell culture workflows<br /><br /></li><li>Engineered signaling proteins help address key challenges in scaling cell therapy from discovery through manufacturing</li></ul><p><span class="legendSpanClass"><location value="LU/us.mn.minnea" idsrc="xmltag.org" >MINNEAPOLIS</location></span>, <span class="legendSpanClass"><chron>July 8, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TECH" idsrc="xmltag.org" >Bio-Techne Corporation</span> (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced the launch of new additions http://www.streetinsider.com/PRNewswire/Bio-Techne+Launches+Expanded+R%26amp%3BD+Systems+AI-Engineered+Designer+Protein+Portfolio/26743909.html Wed, 08 Jul 2026 06:30:00 -0400 A.28110669 A.50204289 O.00052604 O.00096475 O.48401414 TECH http://www.streetinsider.com/PRNewswire/Bio-Techne+Launches+Expanded+R%26amp%3BD+Systems+AI-Engineered+Designer+Protein+Portfolio/26743909.html <div class="xn-content"> <p class="prntac"><i>Advancing Scalable Reproducible Cell Therapy and Advanced Cell Culture Workflows</i></p><ul type="disc"><li>New heat-stable and hyperactive proteins across the fibroblast growth factor and interleukin cytokine families expand the R&amp;D Systems™ AI-Engineered Designer Protein portfolio<br /><br /></li><li>AI-guided protein design supports improved consistency, performance and scalability in complex cell culture workflows<br /><br /></li><li>Engineered signaling proteins help address key challenges in scaling cell therapy from discovery through manufacturing</li></ul><p><span class="legendSpanClass"><location value="LU/us.mn.minnea" idsrc="xmltag.org" >MINNEAPOLIS</location></span>, <span class="legendSpanClass"><chron>July 8, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TECH" idsrc="xmltag.org" >Bio-Techne Corporation</span> (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced the launch of new additions http://www.streetinsider.com/PRNewswire/Bio-Techne+Launches+Expanded+R%26amp%3BD+Systems+AI-Engineered+Designer+Protein+Portfolio/26743909.html Wed, 08 Jul 2026 06:30:00 -0400 A.28110669 A.50204289 O.00052604 O.00096475 O.48401414 TECH http://www.streetinsider.com/PRNewswire/Bio-Techne+Launches+Expanded+R%26amp%3BD+Systems+AI-Engineered+Designer+Protein+Portfolio/26743909.html <div class="xn-content"> <p class="prntac"><i>Advancing Scalable Reproducible Cell Therapy and Advanced Cell Culture Workflows</i></p><ul type="disc"><li>New heat-stable and hyperactive proteins across the fibroblast growth factor and interleukin cytokine families expand the R&amp;D Systems™ AI-Engineered Designer Protein portfolio<br /><br /></li><li>AI-guided protein design supports improved consistency, performance and scalability in complex cell culture workflows<br /><br /></li><li>Engineered signaling proteins help address key challenges in scaling cell therapy from discovery through manufacturing</li></ul><p><span class="legendSpanClass"><location value="LU/us.mn.minnea" idsrc="xmltag.org" >MINNEAPOLIS</location></span>, <span class="legendSpanClass"><chron>July 8, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TECH" idsrc="xmltag.org" >Bio-Techne Corporation</span> (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced the launch of new additions http://www.streetinsider.com/PRNewswire/Bio-Techne+Launches+Expanded+R%26amp%3BD+Systems+AI-Engineered+Designer+Protein+Portfolio/26743909.html Wed, 08 Jul 2026 06:30:00 -0400 A.28110669 A.50204289 O.00052604 O.00096475 O.48401414 TECH http://www.streetinsider.com/PRNewswire/Bio-Techne+Launches+Expanded+R%26amp%3BD+Systems+AI-Engineered+Designer+Protein+Portfolio/26743909.html <div class="xn-content"> <p class="prntac"><i>Advancing Scalable Reproducible Cell Therapy and Advanced Cell Culture Workflows</i></p><ul type="disc"><li>New heat-stable and hyperactive proteins across the fibroblast growth factor and interleukin cytokine families expand the R&amp;D Systems™ AI-Engineered Designer Protein portfolio<br /><br /></li><li>AI-guided protein design supports improved consistency, performance and scalability in complex cell culture workflows<br /><br /></li><li>Engineered signaling proteins help address key challenges in scaling cell therapy from discovery through manufacturing</li></ul><p><span class="legendSpanClass"><location value="LU/us.mn.minnea" idsrc="xmltag.org" >MINNEAPOLIS</location></span>, <span class="legendSpanClass"><chron>July 8, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TECH" idsrc="xmltag.org" >Bio-Techne Corporation</span> (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced the launch of new additions http://www.streetinsider.com/PRNewswire/Bio-Techne+Launches+Expanded+R%26amp%3BD+Systems+AI-Engineered+Designer+Protein+Portfolio/26743909.html Wed, 08 Jul 2026 06:30:00 -0400 A.28110669 A.50204289 O.00052604 O.00096475 O.48401414 TECH http://www.streetinsider.com/Downgrades/Evercore+ISI+Downgrades+Bio-Techne+Corp.+%28TECH%29+to+In+Line/26731930.html <p>Evercore ISI analyst Vijay Kumar downgraded Bio-Techne Corp. (NASDAQ: TECH) from Outperform to In Line with a price target of $73.00.</p><p>For an analyst ratings summary and ratings history on Bio-Techne Corp. <a href="http://www.streetinsider.com/rating_history.php?q=TECH">click here</a>. For more ratings news on Bio-Techne Corp. <a href="http://www.streetinsider.com/stock_lookup_news.php?q=TECH&amp;type=analyst">click here</a>.</p><p>Shares of Bio-Techne Corp. closed at $70.83 yesterday.</p> http://www.streetinsider.com/Downgrades/Evercore+ISI+Downgrades+Bio-Techne+Corp.+%28TECH%29+to+In+Line/26731930.html Mon, 06 Jul 2026 05:58:13 -0400 TECH http://www.streetinsider.com/Press+Releases/Shareholder+Alert%3A+Ademi+LLP+investigates+whether+Bio-Techne+Corporation+is+obtaining+a+Fair+Price+for+Public+Shareholders/26723200.html <p>MILWAUKEE, July 02, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Bio-Techne (NASDAQ: TECH) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Merck.</p> <p>Click <a href="https://www.globenewswire.com/Tracker?data=3gSgj4UHcdw_seX8bAGBxYGSPAwTDpxa0QBly57VmKvbkN1ut1upgMNxdD_-RlSJsT1aPuBb49uBySicWj05SvLZSqJph6zdnJNVmreJOgwSgWegVZtU4Qe7FAEF63e1" rel="nofollow" target="_blank">here</a> to learn how to join our investigation and obtain additional information or contact us at <a href="https://www.globenewswire.com/Tracker?data=9XQFAW_U894hLkskjSKNReCKdB1b1IATyLCV05G1MQL-eW_NJHMN0enmOcZi_wup2YYGIketx--FZmj0dOEy8CjMdgGQ-phsCaaCZwkXn9U=" rel="nofollow" target="_blank">gademi@ademilaw.com</a> or toll-free: 866-264-3995. There is no cost or obligation to you.</p> <p>Bio-Techne shareholders will receive $73 per share in cash, representing a total enterprise value of approximately $11.3 billion. Bio-Techne insiders will receive substantial benefits as part of change of http://www.streetinsider.com/Press+Releases/Shareholder+Alert%3A+Ademi+LLP+investigates+whether+Bio-Techne+Corporation+is+obtaining+a+Fair+Price+for+Public+Shareholders/26723200.html Thu, 02 Jul 2026 05:31:48 -0400 TECH http://www.streetinsider.com/Globe+Newswire/Shareholder+Alert%3A+Ademi+LLP+investigates+whether+Bio-Techne+Corporation+is+obtaining+a+Fair+Price+for+Public+Shareholders/26723200.html <p>MILWAUKEE, July 02, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Bio-Techne (NASDAQ: TECH) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Merck.</p> <p>Click <a href="https://www.globenewswire.com/Tracker?data=3gSgj4UHcdw_seX8bAGBxYGSPAwTDpxa0QBly57VmKvbkN1ut1upgMNxdD_-RlSJsT1aPuBb49uBySicWj05SvLZSqJph6zdnJNVmreJOgwSgWegVZtU4Qe7FAEF63e1" rel="nofollow" target="_blank">here</a> to learn how to join our investigation and obtain additional information or contact us at <a href="https://www.globenewswire.com/Tracker?data=9XQFAW_U894hLkskjSKNReCKdB1b1IATyLCV05G1MQL-eW_NJHMN0enmOcZi_wup2YYGIketx--FZmj0dOEy8CjMdgGQ-phsCaaCZwkXn9U=" rel="nofollow" target="_blank">gademi@ademilaw.com</a> or toll-free: 866-264-3995. There is no cost or obligation to you.</p> <p>Bio-Techne shareholders will receive $73 per share in cash, representing a total enterprise value of approximately $11.3 billion. Bio-Techne insiders will receive substantial benefits as part of change of http://www.streetinsider.com/Globe+Newswire/Shareholder+Alert%3A+Ademi+LLP+investigates+whether+Bio-Techne+Corporation+is+obtaining+a+Fair+Price+for+Public+Shareholders/26723200.html Thu, 02 Jul 2026 05:31:48 -0400 TECH http://www.streetinsider.com/Downgrades/Benchmark+Downgrades+Bio-Techne+Corp.+%28TECH%29+to+Hold/26709473.html <p>Benchmark analyst Robert Wasserman downgraded Bio-Techne Corp. (NASDAQ: TECH) from Buy to Hold.</p><p>For an analyst ratings summary and ratings history on Bio-Techne Corp. <a href="http://www.streetinsider.com/rating_history.php?q=TECH">click here</a>. For more ratings news on Bio-Techne Corp. <a href="http://www.streetinsider.com/stock_lookup_news.php?q=TECH&amp;type=analyst">click here</a>.</p><p>Shares of Bio-Techne Corp. closed at $70.90 yesterday.</p> http://www.streetinsider.com/Downgrades/Benchmark+Downgrades+Bio-Techne+Corp.+%28TECH%29+to+Hold/26709473.html Tue, 30 Jun 2026 07:06:16 -0400 TECH http://www.streetinsider.com/Downgrades/TD+Cowen+Downgrades+Bio-Techne+Corp.+%28TECH%29+to+Hold/26706885.html <p>TD Cowen analyst Kyle Boucher downgraded Bio-Techne Corp. (NASDAQ: TECH) from Buy to Hold with a price target of $73.00.</p><p>For an analyst ratings summary and ratings history on Bio-Techne Corp. <a href="http://www.streetinsider.com/rating_history.php?q=TECH">click here</a>. For more ratings news on Bio-Techne Corp. <a href="http://www.streetinsider.com/stock_lookup_news.php?q=TECH&amp;type=analyst">click here</a>.</p><p>Shares of Bio-Techne Corp. closed at $71.00 yesterday.</p> http://www.streetinsider.com/Downgrades/TD+Cowen+Downgrades+Bio-Techne+Corp.+%28TECH%29+to+Hold/26706885.html Mon, 29 Jun 2026 16:30:58 -0400 TECH http://www.streetinsider.com/Downgrades/Stephens+Downgrades+Bio-Techne+Corp.+%28TECH%29+to+Equal+Weight/26695282.html <p>Stephens analyst Hannah Helfey downgraded Bio-Techne Corp. (NASDAQ: TECH) from Overweight to Equal Weight with a price target of $73.00 (from $68.00).</p> <p>For an analyst ratings summary and ratings history on Bio-Techne Corp. <a href="http://www.streetinsider.com/rating_history.php?q=TECH">click here</a>. For more ratings news on Bio-Techne Corp. <a href="http://www.streetinsider.com/stock_lookup_news.php?q=TECH&amp;type=analyst">click here</a>.</p> <p>Shares of Bio-Techne Corp. closed at $70.70 yesterday.</p> http://www.streetinsider.com/Downgrades/Stephens+Downgrades+Bio-Techne+Corp.+%28TECH%29+to+Equal+Weight/26695282.html Fri, 26 Jun 2026 08:24:21 -0400 TECH http://www.streetinsider.com/Analyst+PT+Change/Stephens+Downgrades+Bio-Techne+Corp.+%28TECH%29+to+Equal+Weight/26695282.html <p>Stephens analyst Hannah Helfey downgraded Bio-Techne Corp. (NASDAQ: TECH) from Overweight to Equal Weight with a price target of $73.00 (from $68.00).</p> <p>For an analyst ratings summary and ratings history on Bio-Techne Corp. <a href="http://www.streetinsider.com/rating_history.php?q=TECH">click here</a>. For more ratings news on Bio-Techne Corp. <a href="http://www.streetinsider.com/stock_lookup_news.php?q=TECH&amp;type=analyst">click here</a>.</p> <p>Shares of Bio-Techne Corp. closed at $70.70 yesterday.</p> http://www.streetinsider.com/Analyst+PT+Change/Stephens+Downgrades+Bio-Techne+Corp.+%28TECH%29+to+Equal+Weight/26695282.html Fri, 26 Jun 2026 08:24:21 -0400 TECH http://www.streetinsider.com/Analyst+PT+Change/Bio-Techne+Corp.+%28TECH%29+PT+Raised+to+%2473+at+Baird/26694773.html Baird analyst Catherine Schulte raised the price target on Bio-Techne Corp. (NASDAQ: TECH) to $73.00 (from $49.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/Bio-Techne+Corp.+%28TECH%29+PT+Raised+to+%2473+at+Baird/26694773.html Fri, 26 Jun 2026 06:37:27 -0400 TECH